Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
CN¥ 30.78
Key Takeaways
Risk factor
High price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Favourable price performance
Data is available to registered users only
Data is available to registered users only
About
Olymvax Biopharmaceuticals Inc. develops and supplies vaccines. The company offers vaccines for Tetanus, a deadly infectious disease that causes nervous system toxicity by toxigenic clostridium tetanus; and haemophilus influenzae type b. it also develops vaccines for Staphylococcus aureus, a pathogenic bacterium that causes hospital infection and community infection; and Group A streptococcus disease. The company...
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks. Specifically, the stock is 'expensive' on P/E, overvalued
Data is available to registered users only
Buy
Sell